Literature DB >> 3041635

Role of intraoperative fibrinolytic therapy in acute arterial occlusion.

R F Norem1, D H Short, M D Kerstein.   

Abstract

Nineteen patients with acute onset of ischemia affecting the lower extremities were studied from January 1985 to March 1987. Patients with preoperative Doppler and angiographic studies consistent with arterial occlusions subsequently underwent a thromboembolectomy using a Fogarty catheter. All patients were given a bolus injection of 5,000 units of heparin intravenously at the start of the surgical procedure. In all patients studied, a clot was retrieved on the first pass, but after two additional passes, total distal blood flow was not shown to be restored on angiogram. Intraoperative angiograms showed distal emboli. All patients underwent intraoperative fibrinolytic therapy by local bolus infusion. Streptokinase, ranging from 50,000 to 200,000 units, was administered in 50,000 unit injections in ten to 15 minute intervals. Repeat attempts at thromboembolectomy with the Fogarty catheter resulted in an additional clot retrieved in all 19 patients with intraoperative angiographic, Doppler and clinical improvement. No perioperative or postoperative complications were observed, including anaphylactic reactions, uncontrollable bleeding or amputation. Four patients had nonacute femoropopliteal bypass operations within the next six months. Intraoperative fibrinolytic therapy can be a safe and effective adjunct in acute arterial embolic occlusion requiring balloon catheter thromboembolectomy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3041635

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  1 in total

1.  A prospective, randomized, blinded, and placebo-controlled trial of intraoperative intra-arterial urokinase infusion during lower extremity revascularization. Regional and systemic effects.

Authors:  A J Comerota; A K Rao; R C Throm; C I Skibinski; G J Beck; S Ghosh; L Sun; G R Curl; J J Ricotta; R A Graor
Journal:  Ann Surg       Date:  1993-10       Impact factor: 12.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.